"Developing novel treatments for Dormant Cancers - targeting resistance, metastasis, and relapse."

 

Cancer cell dormancy is a major and as yet unaddressed mechanism of cancer survival and acquired resistance which develops over time on exposure to chemotherapeutics.

 
Felicitex is developing new therapies that kill cancer cells depriving them from the ability to enter the dormant state for their survival niche. Our therapies target both growing and dormant, otherwise non-responsive cancer cells with three therapeutically beneficial outcomes: first, kill dormant cancer cells and thereby eliminate their ability to develop resistant phenotype; second, decrease their metastatic potential; and third, eliminate cancer recurrence. 
 
Cellular dormancy is a resting or “sleeping” state, denoted as the G0 state of the cell cycle. While being dormant, a cell is in a reversible low metabolic state. As a consequence, both transcription and translation processes are slowed making these cells are resistant to damage by chemotherapeutics and targeted therapies. 
Slide1
Slide1

Slide2
Slide2

Slide1
Slide1

1/2
Click above to view slides

 © 2019 by Felicitex Therapeutics, Inc »«                     27 Strathmore Road  Natick, MA 01760      1-919-213-0025 (p)                                           Click here to Contact Us!